| Project/Area Number |
11671255
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | OITA MEDICAL UNIVERSITY |
|---|
Principal Investigator |
KITANO Seigo (2000) Oita Medical University, Dept.of Surg.I, Professor, 医学部, 教授 (90169871)
吉田 隆典 (1999) 大分医科大学, 医学部, 助教授 (90220649)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWANO Katsunori Oita Medical University, Dept.of Surg.I, Assistant Professor, 医学部, 講師 (00274754)
ARAMAKI Masanori Oita Medical University, Dept.of Surg.I, Assistant Professor, 医学部, 助手 (10291543)
北野 正剛 大分医科大学, 医学部, 教授 (90169871)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2000: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1999: ¥2,700,000 (Direct Cost: ¥2,700,000)
|
|---|
| Keywords | Biliary-pancreatic cancer / Micrometastasis / Molecular biology / K-ras / Mutation |
|---|
| Research Abstract |
It is possible that some of patients with biliary-pancreatic cancers are non-resectable cases, because those cancers are discovered in advanced stage. Therefore, in this prospective study, we do not have obtained enough samples until now.
We performed the detection of K-ras mutations in past samples of patients with pancreatic and gallbladder cancer. The following methods were employed. Each DNA was extracted from tumor and non-tumor portions of paraffin- embedded tissues and K-ras mutation was detected using nested mutant allele specific amplification PCR (Nested MASA). In tumor tissues from panceatic cancers, K-ras mutations were detected in 78.4% (40/51). In tumor tissues from gallbladder cancers (GBC) with and without anomalous junction of pancreaticobiliary duct (AJPBD), the incidence of K-ras mutations was 88.9% (8/9) and 15.0% (3/20), respectively. The incidence of K-ras mutations was significantly higher in tumor tissues of GBC patients with AJPBD than in those of GBC patients without AJPBD.Furthermore, K-ras mutations were detected in 62.5% (5/8) in non-tumor tissues of GBC patients with AJPBD.In conclusion, it was suggested that K-ras mutation may play an important role in tumorigenesis of pancreatic cancers and gallbladder cancers with AJPBD.
|
